Amarin (NASDAQ:AMRN – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $32.37 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Amarin Stock Performance
NASDAQ:AMRN opened at $0.47 on Tuesday. Amarin has a one year low of $0.40 and a one year high of $1.11. The firm has a market cap of $191.04 million, a price-to-earnings ratio of -5.17 and a beta of 1.82. The firm’s fifty day moving average is $0.56 and its two-hundred day moving average is $0.56.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Amarin from a “sell” rating to a “hold” rating in a report on Friday.
About Amarin
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
See Also
- Five stocks we like better than Amarin
- How to find penny stocks to invest and trade
- How to Protect Your Portfolio When Inflation Is Rising
- Basic Materials Stocks Investing
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- 3 Small Caps With Big Return Potential
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
